JP2012162567A5 - - Google Patents

Download PDF

Info

Publication number
JP2012162567A5
JP2012162567A5 JP2012121307A JP2012121307A JP2012162567A5 JP 2012162567 A5 JP2012162567 A5 JP 2012162567A5 JP 2012121307 A JP2012121307 A JP 2012121307A JP 2012121307 A JP2012121307 A JP 2012121307A JP 2012162567 A5 JP2012162567 A5 JP 2012162567A5
Authority
JP
Japan
Prior art keywords
cancer
composition
recombinant interferon
injection
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012121307A
Other languages
English (en)
Japanese (ja)
Other versions
JP5709800B2 (ja
JP2012162567A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012162567A publication Critical patent/JP2012162567A/ja
Publication of JP2012162567A5 publication Critical patent/JP2012162567A5/ja
Application granted granted Critical
Publication of JP5709800B2 publication Critical patent/JP5709800B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2012121307A 2003-08-28 2012-05-28 変えられた空間構造を備えるインターフェロン及びその応用 Expired - Fee Related JP5709800B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US49878503P 2003-08-28 2003-08-28
US49892303P 2003-08-28 2003-08-28
US49844903P 2003-08-28 2003-08-28
US60/498,785 2003-08-28
US60/498,923 2003-08-28
US60/498,449 2003-08-28
IN279/MUM/2004 2004-03-05
IN280/MUM/2004 2004-03-05
IN280MU2004 2004-03-05
IN279MU2004 2004-03-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006524916A Division JP5663768B2 (ja) 2003-08-28 2004-08-26 空間構造が変えられるインターフェロン及びその応用

Publications (3)

Publication Number Publication Date
JP2012162567A JP2012162567A (ja) 2012-08-30
JP2012162567A5 true JP2012162567A5 (enExample) 2015-02-19
JP5709800B2 JP5709800B2 (ja) 2015-04-30

Family

ID=34280101

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006524916A Expired - Fee Related JP5663768B2 (ja) 2003-08-28 2004-08-26 空間構造が変えられるインターフェロン及びその応用
JP2006524917A Pending JP2007503812A (ja) 2003-08-28 2004-08-26 空間構造によるタンパク質の機能の調節
JP2011011325A Pending JP2011083292A (ja) 2003-08-28 2011-01-21 空間構造によるタンパク質の機能の調節
JP2012121307A Expired - Fee Related JP5709800B2 (ja) 2003-08-28 2012-05-28 変えられた空間構造を備えるインターフェロン及びその応用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2006524916A Expired - Fee Related JP5663768B2 (ja) 2003-08-28 2004-08-26 空間構造が変えられるインターフェロン及びその応用
JP2006524917A Pending JP2007503812A (ja) 2003-08-28 2004-08-26 空間構造によるタンパク質の機能の調節
JP2011011325A Pending JP2011083292A (ja) 2003-08-28 2011-01-21 空間構造によるタンパク質の機能の調節

Country Status (7)

Country Link
EP (3) EP1663110B1 (enExample)
JP (4) JP5663768B2 (enExample)
KR (2) KR20060133949A (enExample)
AU (2) AU2004279350B2 (enExample)
CA (2) CA2535902A1 (enExample)
PL (2) PL2325202T3 (enExample)
WO (2) WO2005034853A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
EP1663110B1 (en) * 2003-08-28 2013-12-18 Superlab Far East Limited Uses of interferons with altered spatial structure
WO2006076014A2 (en) * 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars
JP5209462B2 (ja) 2005-03-09 2013-06-12 ウェイ グアンウェン コンセンサスインターフェロンの使用方法
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
TW201427681A (zh) * 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
CN111363726A (zh) 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US6579695B1 (en) * 1995-10-13 2003-06-17 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US20020043262A1 (en) * 2000-08-22 2002-04-18 Alan Langford Spray device
EP2292652A2 (en) * 2000-11-03 2011-03-09 Pestka Biomedical Laboratories, Inc. Interferons uses and compositions related thereto
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
EP1663110B1 (en) * 2003-08-28 2013-12-18 Superlab Far East Limited Uses of interferons with altered spatial structure

Similar Documents

Publication Publication Date Title
JP2012162567A5 (enExample)
JP2020515574A5 (enExample)
JP2015536964A5 (enExample)
TR201906470T4 (tr) İmmünomodülatörler.
JP2016128507A5 (enExample)
JP2013189456A5 (enExample)
JP2014193925A5 (enExample)
JP2013544846A5 (enExample)
Rougier et al. Hepatocellular carcinoma (HCC): an update
JP2016518324A5 (enExample)
JP2019511483A5 (enExample)
JP2021063120A5 (enExample)
JP2016519653A5 (enExample)
JP2018516963A5 (enExample)
JP2017525730A5 (enExample)
JP2012184264A5 (enExample)
JP2011500713A5 (enExample)
JP2018517746A5 (enExample)
JP2017538677A5 (enExample)
JP2017530171A5 (enExample)
JP2014518544A5 (enExample)
RU2016131756A (ru) Применение альфавируса в получении противоопухолевых лекарственных средств
RU2018102963A (ru) Производные анилинпиримидина и их применения
JP2014509653A5 (enExample)
JP2013516454A5 (enExample)